🔗 Permalink

Inventor profile of:

Vincent Weynants

City:

Rixensart

Country:

Belgium

Published Applications:

Last publication date:

2019-01-10

Top Assignees for applications by Vincent Weynants

The entities that hold a legal rights for patent applications filed by inventor Weynants Vincent:

GlaxoSmithKline Biologicals S.A. 12 Rixensart, Belgium
Glaxo Smith Kline Biologicals S.A. 1 Rixensart, Belgium
UTRECHT UNIVERSITY 1 Utrecht, Netherlands

Recent patent applications by Weynants Vincent

Vincent Weynants from Rixensart, BE has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2019-01-10

US20190008943A1

Human necessities

VACCINE

#2 | 2017-07-27

US20170209562A1

Human necessities

IMMUNOGENIC COMPOSITION

#3 | 2017-03-23

US20170080075A1

Human necessities

VACCINE

#4 | 2016-08-25

US20160243211A1

Human necessities

VACCINE COMPRISING PROTEIN NMB0964 FROM NEISSERIA MENINGITIDIS

#5 | 2016-03-24

US20160082097A1

Human necessities

NEISSERIAL VACCINE COMPOSITIONS COMPRISING A COMBINATION OF ANTIGENS

#6 | 2013-02-21

US20130045231A1

Human necessities

Immunogenic composition

#7 | 2013-01-10

US20130011429A1

Human necessities

IMMUNOGENIC COMPOSITION

#8 | 2013-01-03

US20130004530A1

Human necessities

VACCINE COMPOSITION

#9 | 2013-01-03

US20130004510A1

Human necessities

Vaccine

#10 | 2012-03-15

US20120064120A1

Human necessities

NEISSERIAL VACCINE COMPOSITIONS COMPRISING A COMBINATION OF ANTIGENS

#11 | 2012-03-15

US20120064119A1

Human necessities

NEISSERIAL VACCINE COMPOSITIONS COMPRISING A COMBINATION OF ANTIGENS

#12 | 2012-02-02

US20120027800A1

Human necessities

NEISSERIAL VACCINE COMPOSITIONS COMPRISING A COMBINATION OF ANTIGENS

#13 | 2011-08-04

US20110189215A1

Human necessities

Vaccine comprising protein NMB0964 from

#14 | 2011-07-07

US20110165590A1

Physics

Vaccine protection assay

#15 | 2011-02-10

US20110033500A1

Human necessities

Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from LGTB-neisseria meningitidis

#16 | 2010-11-18

US20100291137A1

Human necessities

METHOD FOR REFOLDING NEISSERIAL NSPA PROTEIN

#17 | 2009-10-01

US20090246224A1

Human necessities

VACCINE

#18 | 2009-05-14

US20090123499A1

Human necessities

VACCINE

#19 | 2008-09-11

US20080220457A1

Physics

Serum bactericidal assay for specific antisera

#20 | 2008-03-13

US20080064057A1

Physics

Vaccine protection assay

#21 | 2008-01-31

US20080025993A1

Human necessities

Method for Refolding Neisserial Nspa Protein

#22 | 2006-10-26

US20060240045A1

Human necessities

Neisserial vaccine compositions comprising a combination of antigens

#23 | 2006-06-29

US20060141563A1

Human necessities

Mutant protein and refolding method

#24 | 2006-03-16

US20060057160A1

Human necessities

Vaccine composition

#25 | 2006-03-09

US20060051379A1

Human necessities

Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from LGTB-

#26 | 2006-02-16

US20060034854A1

Human necessities

Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria

InventorID:

10669 ⎘